Jackson Center, PA, May 10, 2021 – Halberd Corporation (OTC-PINK: “HALB“) was recently discussed in Penny Stocks News and Wall Street Trader publications as a BREAKOUT stock to watch with a projected share price of HALB to rise above the $0.06/share level. Halberd Corporation did not participate in these determinations, nor does it subscribe thereto, nor was it solicited. The article went on to cite Halberd’s numerous patents, the recent appointment of Dr. Mitchell S. Felder as Chief Technical Officer, and Dr. William G. Sturrus of Youngstown State University to lead the application projects of applying Radio Frequency (RF) and lasers to eliminate disease as the basis of the assessment.

William A. Hartman, Halberd Corporation’s Chairman, President & CEO, remarked, “We are pleased that our efforts and potential are being recognized in investor publications. Halberd Corporation is committed to moving our patented extracorporeal process, and its various related patent pending applications forward to a multiplicity of successful applications.”

According to Dr. Mitchell S. Felder, Halberd’s Chief Technology Officer and principal inventor, “Halberd’s unique and proprietary process involves bodily fluids exposed to tuned Radio Frequency waves and/or laser energy, in a hospital or clinic environment, in order to eradicate virtually any disease targeted, without dangerous side-effects common to the application of conventional internal medications.  If our imminent proof-of-concept tests are successful, we believe adoption of Halberd’s technology could pave the way for developing successful treatments against virtually any viral or bacterial infection, thus revolutionizing medicine worldwide.  Additional information regarding the commencement of testing and initial results will be released shortly.”

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.

For more information please contact:
William A. Hartman

About Halberd Corporation.

Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

­­­Title Patent/ Application No. Filing DateStatus/Document
*Method for Treating and Curing Covid-19 InfectionUS 62/98998103/16/2020Provisional
PCT/US21/2254103/16/2021International  PCT
*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 PatientsUS 63/00720704/08/2020Provisional
Covid-19 Inflammatory Cytokine Storm TreatmentPCT/US21/2638604/08/2021International PCT
*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the VirusUS 63/01310404/21/2020Provisional
Treating and Curing Covid-19 Infection Utilizing a LaserPCT/US21/2836804/21/2021International PCT
*Method For The Rapid Identification Of Covid-19 InfectionUS 63/04944107/08/2020Provisional
*Nasal Spray To Prevent The Transmission Of Covid-19 Between HumansUS 63/08073509/20/2020Provisional
*Nasal Spray To Prevent The Transmission Of The Covid-19 VirusUS 63/10830110/31/202Provisional
*Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The VirusUS 63/11104311/08/2020Provisional
*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)US 63/13569501/10/2021Provisional

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.


Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.